Neurocrine Biosciences, Inc. (NBIX)

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to

Market

Industry

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$11.5 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt.	$10.5 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	$0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield.	-8.2%
52-Week High Highest share price in the last 52 weeks.	$127.44
52-Week Low Lowest share price in the last 52 weeks.	$89.04
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return.	0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders.	98.3 Million
Avg 30 Day Volume The number of shares traded in the last 30 days.	702 Thousand

Valuation

Compare to

Market

Industry

P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	59.97
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	281.39
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value.	$1.90
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	6.47
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	5.83
Enterprise Value to Revenue Enterprise value divided by revenue	5.9
Enterprise Value to EBIT Enterprise Value divided by EBIT	30.27
Total Debt to Enterprise Value Total debt divided by enterprise value	0.02
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	0.08

Profitability

Compare to

Market

Industry

Revenue Revenue is the sum of all cash flow into the company.	$1.78 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services.	$1.75 Billion
EBIT Earnings before tax and interest payments.	$348 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue.	$191 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	10.71%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	+21.3%
Return on Equity Equity divided by market cap.	9.54%
Return on Assets Indicates a company's profitability in relation to its total assets.	6.71%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	16.13%

Insider trades

Q1 2023 Q2 2023 Q3 2023 Q4 2023

About Neurocrine Biosciences, Inc.

CEO: Kevin Gorman

Industry: Biological Product (except Diagnostic) Manufacturing

Similar stocks

Repligen Corp.

Royalty Pharma plc - Class A

Palatin Technologies Inc.

Lilly(Eli) & Co

Abbvie Inc

Pfizer Inc.

CASI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Athersys Inc

News

Pro Research: Wall Street dives into Neurocrine Biosciences

https://www.investing.com/news/stock-market-news/pro-research-wall-street-dives-into-neurocrine-biosciences-93CH-3249162

Investing.com, 1 day ago

Insider Sell Alert: Chief Scientific Officer Jude Onyia Sells Shares of Neurocrine Biosciences Inc

GuruFocus, 4 days ago

Neurocrine Biosciences: Fear Not The IRA

Fears of IRA''s impact on Neurocrine''s Ingrezza are overblown and it is well positioned to grow in the following decade. Find out if NBIX stock is a buy.

Seeking Alpha, 6 days ago